Keywords
Bone cancer
Breast Cancer
General Oncology
Gynecological Cancers
Head and neck cancer
Lung Cancer
Radiation Oncology
Authors:
Harshini Asogan1 MD, Issa Al Salmi2,3* MD, FRCPI, MRCP (UK), FRCP, MIPH, PHD (AUS), FASN (USA), Divij Krishna Jha2 MD, Fatma Al Rahbi2 and Suad Hannawi4 MD, MRCP (UK), FRCP, MIPH, PHD (AUS)
The Royal Hospital, 23 July Street, P O Box 1331, code 111, Muscat, Oman
Correspondence to Author: Issa Al Salmi
Abstract:
1.1. Introduction: Beta2-microglobulin (β-2M) production is constant among healthy population, making it appropriate proxy for the estimated Glomerular-Filtration-Rate (eGFR).
1.2. Methodology: This clinical observational study was conducted at the Royal Hospital, Muscat. It aims to define the level of serum-β-2M along with their clinical and investigatory profiles. Data collected prospectively via electronic system.
1.3. Results: 866 had Chronic-Kidney-Disease (CKD), of which 476 (55%) were males. A total of 552 had stage-1CKD with β-2M (mg/dl) levels found to be 3.04(5) in 287 male patients and 2.68(3.9) in 265 females. Stage-2 CKD, a total of 121 patients with 69 males and 52 females had β-2M levels 4.15 (2.9) and 4.06 (3.3) respectively. A total of 91 patients with Stage-3CKD, of which 61 were males and 30 were females, with β-2M levels being 7.14 (5.3) and 8.96 (7.2) respectively.
1.4. Conclusions: Kidney-function is the main determinant of serum β-2M by affecting both filtration via glomeruli of the kidney and the generation of β-2M. Uremic solutes that are retained in kidney failure institutes a key cause for the sharp increase of β-2M in CKD. Management strategies for various hematological disorders, in particular during chemotherapy, need to take into consideration maintenance of a good kidney-function
Keywords:
Beta2-Microglobulin (β-2M); estimated GlomerularFiltration-Rate (eGFR); Chronic-Kidney-Disease (CKD); Uremic solutes; Multiple Myeloma; Hodgkin’s lymphoma; Non-Hodgkin’s Lymphoma; Solid Tumors
Citation:
Issa Al Salmi. Beta-2-Microglobulin Level Increases with Advanced CKD Stages: The Implications and Significance. World Journal of Medical Oncology 2020.
Journal Info
- Journal Name: World Journal of Medical Oncology
- Impact Factor: 2.709**
- ISSN: 2766-6077
- DOI: 10.52338/wjoncgy
- Short Name: WJMOY
- Acceptance rate: 55%
- Volume: 6 (2024)
- Submission to acceptance: 25 days
- Acceptance to publication: 10 days
INDEXING
OUR PUBLICATION BENEFITS
- International Reach
- Peer Review
- Rapid Publication
- Open Access
- High Visibility